DrugPatentWatch Database Preview
Drugs in Development Information for GLPG1690
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug GLPG1690?
GLPG1690 is an investigational drug.
There have been 9 clinical trials for GLPG1690.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2018.
The most common disease conditions in clinical trials are Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Idiopathic Interstitial Pneumonias. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].
There are four US patents protecting this investigational drug and thirty-five international patents.
Summary for GLPG1690
| US Patents | 4 |
| International Patents | 35 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2018-11-01) |
| Vendors | 17 |
Recent Clinical Trials for GLPG1690
| Title | Sponsor | Phase |
|---|---|---|
| A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis | Galapagos NV | Phase 2 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Patients With Systemic Sclerosis | Galapagos NV | Phase 2 |
| A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection | Galapagos NV | Phase 1 |
Clinical Trial Summary for GLPG1690
Top disease conditions for GLPG1690
Top clinical trial sponsors for GLPG1690
US Patents for GLPG1690
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GLPG1690 | Start Trial | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (Mechelen, BE) | Start Trial |
| GLPG1690 | Start Trial | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | Galapagos NV (Mechelen, BE) | Start Trial |
| GLPG1690 | Start Trial | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (Mechelen, BE) | Start Trial |
| GLPG1690 | Start Trial | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (Mechelen, BE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GLPG1690
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GLPG1690 | Argentina | 095280 | 2033-03-14 | Start Trial |
| GLPG1690 | Australia | 2014231009 | 2033-03-14 | Start Trial |
| GLPG1690 | Australia | 2017286828 | 2033-03-14 | Start Trial |
| GLPG1690 | Australia | 2019204539 | 2033-03-14 | Start Trial |
| GLPG1690 | Brazil | 112015020998 | 2033-03-14 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
